Premium
O1–11–06: Selective drug inhibition of rho kinase II (ROCK2) reduces beta‐amyloid production in the brain
Author(s) -
Herskowitz Jeremy,
Feng Yangbo,
Higginbotham Lenora,
Seyfried Nicholas,
Levey Allan,
Lah James
Publication year - 2013
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.04.115
Subject(s) - kinase , microbiology and biotechnology , rock2 , amyloid precursor protein , biology , rock1 , protein kinase a , chemistry , rho associated protein kinase , alzheimer's disease , medicine , disease
worse than apoE4-TR mice. Ab12-28P treatment of APP SW/PS1 dE9/ apoE4-TR mice normalized OR behavior and improved RAM performance to the level of apoE4-TR mice. Levels of soluble and insoluble Ab x-40 and Ab x-42 measured by ELISA in the whole brain extract and the burden of Thioflavin-S positive plaques were significantly higher in APP SW/PS1 dE9/apoE4-TR than in APP SW/PS1 dE9/apoE2-TR mice. Ab12-28P treatment was associated with significant reduction in soluble and insoluble Ab x-40 and Ab x-42 levels and lower Thioflavin-S plaque burden in the neocortex and in the hippocampus in both APP SW/PS1 dE9/apoE2-TR and APP SW/PS1 dE9/apoE4-TR lines. Conclusions: Our results indicate that future therapies targeting the apoE/Ab interaction could produce favorable outcome in both APOE2 and APOE4 carriers.